Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Long-Term Capital Lease Obligation : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eiger BioPharmaceuticals Long-Term Capital Lease Obligation?

Eiger BioPharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Eiger BioPharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Eiger BioPharmaceuticals's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($0.12 Mil) to Dec. 2022 ($0.08 Mil) and declined from Dec. 2022 ($0.08 Mil) to Dec. 2023 ($0.00 Mil).

Eiger BioPharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Eiger BioPharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eiger BioPharmaceuticals Long-Term Capital Lease Obligation Chart

Eiger BioPharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.32

0.74

0.12

0.08

Eiger BioPharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.08	-	-	-	-

Eiger BioPharmaceuticals (OTCPK:EIGRQ) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Eiger BioPharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eiger BioPharmaceuticals Inc (OTCPK:EIGRQ) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

72C:Germany 72C:Germany

Address

2155 Park Boulevard, Palo Alto, CA, USA, 94306

Website

https://www.eigerbio.com

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Executives

Richard A Kayne	10 percent owner
Leen Kawas	10 percent owner	4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Ingrid Choong	officer: Chief Business Officer	24645 SUMMERHILL AVE, LOS ALTOS CA 94024
William G Kachioff	officer: CFO	4060 PORTE DE PALMAS, SAN DIEGO CA 92122
James Vollins	officer: General Counsel	C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mayer Eldon C. Iii	officer: Ex VP & Chief Commerc. Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Jeffrey S Glenn	director	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306
David Apelian	director	C/O ACHILLION PHARMACEUTICALS, INC, 300 GEORGE STREET, NEW HAVEN CT 06511
Sriram Ryali	officer: Chief Financial Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Christine Murray	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Erik Atkisson	officer: GC & Chief Compliance Officer	C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Kim Sablich	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005
David A Cory	director, officer: President and CEO	350 CAMBRIDGE AVENUE, SUITE 350, PALO ALTO CA 94306